ATE205088T1 - Glial neurotropher faktor als nervenschutzmittel - Google Patents

Glial neurotropher faktor als nervenschutzmittel

Info

Publication number
ATE205088T1
ATE205088T1 AT95935548T AT95935548T ATE205088T1 AT E205088 T1 ATE205088 T1 AT E205088T1 AT 95935548 T AT95935548 T AT 95935548T AT 95935548 T AT95935548 T AT 95935548T AT E205088 T1 ATE205088 T1 AT E205088T1
Authority
AT
Austria
Prior art keywords
neurotrophic factor
nervoprotective
agent
gdnf
glial
Prior art date
Application number
AT95935548T
Other languages
English (en)
Inventor
David Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE205088T1 publication Critical patent/ATE205088T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95935548T 1994-11-15 1995-11-13 Glial neurotropher faktor als nervenschutzmittel ATE205088T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34082194A 1994-11-15 1994-11-15
PCT/IB1995/001004 WO1996014861A1 (en) 1994-11-15 1995-11-13 Glial derived neurotrophic factor as a neuroprotective agent

Publications (1)

Publication Number Publication Date
ATE205088T1 true ATE205088T1 (de) 2001-09-15

Family

ID=23335068

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95935548T ATE205088T1 (de) 1994-11-15 1995-11-13 Glial neurotropher faktor als nervenschutzmittel

Country Status (13)

Country Link
US (1) US5733875A (de)
EP (1) EP0792160B1 (de)
JP (1) JPH10508839A (de)
AT (1) ATE205088T1 (de)
AU (1) AU691349B2 (de)
CA (1) CA2204911C (de)
DE (1) DE69522578T2 (de)
DK (1) DK0792160T3 (de)
ES (1) ES2159647T3 (de)
IL (1) IL115966A (de)
PT (1) PT792160E (de)
WO (1) WO1996014861A1 (de)
ZA (1) ZA959714B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
WO1997019693A1 (en) * 1995-11-29 1997-06-05 Amgen Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
BR9713055A (pt) 1996-11-15 2000-04-04 Genentech Inc Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
ES2198367T3 (es) * 1999-10-29 2004-02-01 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Uso de gdnf para tratar defectos de la cornea.
US20040197900A1 (en) * 2003-04-04 2004-10-07 Arnon Rosenthal Foggy
HUE030903T2 (en) * 2006-04-25 2017-06-28 Univ California Administration of growth factors for the treatment of CNS disorders
JP2009535360A (ja) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
EP2291181B9 (de) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine zur Behandlung von depressionartigen Symptomen
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
EP3973979A1 (de) * 2020-09-25 2022-03-30 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth Tight-junction (zonulae occludentes)-protein zur verwendung in der behandlung oder vorbeugung einer neurologischen störung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0610254T3 (da) * 1991-09-20 2005-01-10 Amgen Inc Glial-afledt neurotrofisk faktor
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.

Also Published As

Publication number Publication date
EP0792160B1 (de) 2001-09-05
JPH10508839A (ja) 1998-09-02
EP0792160A1 (de) 1997-09-03
ZA959714B (en) 1997-10-15
DK0792160T3 (da) 2001-11-19
DE69522578T2 (de) 2002-07-11
IL115966A0 (en) 1996-01-31
WO1996014861A1 (en) 1996-05-23
ES2159647T3 (es) 2001-10-16
AU691349B2 (en) 1998-05-14
IL115966A (en) 1999-11-30
AU3752895A (en) 1996-06-06
DE69522578D1 (de) 2001-10-11
US5733875A (en) 1998-03-31
CA2204911C (en) 2002-07-23
PT792160E (pt) 2002-02-28
CA2204911A1 (en) 1996-05-23

Similar Documents

Publication Publication Date Title
ATE205088T1 (de) Glial neurotropher faktor als nervenschutzmittel
PT1115417E (pt) Utilizacao da daptomicina
BG102999A (bg) Нови 2,3 дизаместени-4(3н)-хиназолинони
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
PL326149A1 (en) Pharmaceutic dipeptides containing angiostatic agents and methods of their application
ATE178793T1 (de) L-dopa ester-enthaltende zusammensetzung
NO306677B1 (no) Heterosykliske forbindelser, farmasöytiske preparater og anvendelse av en slik forbindelse til fremstilling av et medikament
EP0830369A4 (de) Nor-pregnane zur induzierung hypothalamischer effekte
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
DE69434652D1 (de) Antikonvulsive pseudofructopyranose sulfamate
AP9300561A0 (en) Antibiotic compounds.
MX9702253A (es) Nuevos estrenos para inducir efectos hipotalamicos
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
SE9203296D0 (sv) The use of inositoltrisphate for the preparing of medicaments
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
MX9703610A (es) Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas.
MY110416A (en) Composition for the treatment of schizophrenia.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee